Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL

Shanmugapriya Thangavadivel, John C. Byrd
2019 Cancer Discovery  
In this issue, Blombery and colleagues show that the chronic lymphocytic leukemia (CLL) cells bearing Gly101Val mutation confer resistance to venetoclax by reducing the affinity of BCL2 for venetoclax by 180-fold in cell lines and in patient cells. Detection of this mutation provides a potential biomarker for impending disease progression and an opportunity for targeted and combinational therapy to treat CLL.See related article by Blombery et al., p. 342.
doi:10.1158/2159-8290.cd-19-0029 pmid:30824485 fatcat:7bmu4tzaaffpdfeucmfi7ndrti